Treatment with the SQ house dust mite sublingual immunotherapy tablet may be initiated year-round

September–October, 2018Volume 6, Issue 5, Pages 1758–1760.e1

Correspondence information about the author MD, PhD Hendrik Nolt

Email the author MD, PhD Hendrik Nolte

Hendrik Nolte, MD, PhD

David I. Bernstein, MD, FAAAAI

, 

Jörg Kleine-Tebbe, MD, FAAAAI

, 

Peter A. Fejerskov, RN, BSN

, 

Qing Li, PhD

, 

Susan Lu, PharmD

, 

Harrold S. Nelson, MD, FAAAAI

Open Access

PlumX Metrics

DOI: https://doi.org/10.1016/j.jaip.2017.12.035

Article Info

• Abstract

• Full Text
• Images
• References

This study, based on pooled data from 5 phase 2/3 trials conducted in North America and Europe, indicates that treatment with the SQ house dust mite sublingual immunotherapy tablet can be safely initiated throughout winter months and during the pollen season (coseasonal initiation).

The trials included in this study were sponsored by Merck & Co., Inc, and ALK Abelló A/S.

Conflicts of interest: H. Nolte and P. A. Fejerskov are employed by ALK. D. I. Bernstein has received consultancy fees from Merck, Glaxo, and Sanofi Aventis; grants from Merck, Inc, Circassia, Teva, GlaxoSmithKline, Pfizer, Amgen, Pearl, Genentech, Allergy Therapeutics, Boehringer Ingelheim, and AstraZeneca; and lecture fees from Merck, Inc, Sanofi, Genzyme, and Regeneron. J. Kleine-Tebbe is a paid board member of ALK, Novartis, Leti, and Bencard advisory boards; has served as a consultant for Merck and Circassia; has received grant support from Circassia; and has received payment for lectures from Allergopharma, ALK, Bencard, HAL Allergy, LETI, Lofarma, Novartis, and Stallergenes Greer. Q. Li and S. Lu are employed by Merck. H. S. Nelson is a consultant for Merck and speaker for ALK.

© 2018 ALK Abelló A/S. Published by Elsevier Inc.

PDF (612 KB)